11. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. Issue 1 (January 2023) Authors: Watts, Justin M; Baer, Maria R; Yang, Jay; Prebet, Thomas; Lee, Sangmin; Schiller, Gary J; Dinner, Shira N; Pigneux, Arnaud; Montesinos, Pau; Wang, Eunice S; Seiter, Karen P; Wei, Andrew H; De Botton, Stephane; Arnan, Montserrat; Donnellan, Will; Schwarer, Anthony P; Récher, Christian; Jonas, Bri... Journal: Lancet Issue: Volume 10:Issue 1(2023) Page Start: e46 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
12. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Issue 5 (May 2016) Authors: Lipton, Jeffrey H; Chuah, Charles; Guerci-Bresler, Agnès; Rosti, Gianantonio; Simpson, David; Assouline, Sarit; Etienne, Gabriel; Nicolini, Franck E; le Coutre, Philipp; Clark, Richard E; Stenke, Leif; Andorsky, David; Oehler, Vivian; Lustgarten, Stephanie; Rivera, Victor M; Clackson, Timothy; Ha... Journal: Lancet oncology Issue: Volume 17:Issue 5(2016:May) Page Start: 612 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
13. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Issue 7 (July 2019) Authors: Cortes, Jorge E; Khaled, Samer; Martinelli, Giovanni; Perl, Alexander E; Ganguly, Siddhartha; Russell, Nigel; Krämer, Alwin; Dombret, Hervé; Hogge, Donna; Jonas, Brian A; Leung, Anskar Yu-Hung; Mehta, Priyanka; Montesinos, Pau; Radsak, Markus; Sica, Simona; Arunachalam, Meena; Holmes, Melissa; Ko... Journal: Lancet oncology Issue: Volume 20:Issue 7(2019) Page Start: 984 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
14. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Issue 5 (May 2015) Authors: Sasaki, Koji; Strom, Sara S; O'Brien, Susan; Jabbour, Elias; Ravandi, Farhad; Konopleva, Marina; Borthakur, Gautam; Pemmaraju, Naveen; Daver, Naval; Jain, Preetesh; Pierce, Sherry; Kantarjian, Hagop; Cortes, Jorge E Journal: Lancet Issue: Volume 2:Issue 5(2015) Page Start: e186 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
15. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study. Issue 1 (January 2015) Authors: DiNardo, Courtney D; Daver, Naval; Jabbour, Elias; Kadia, Tapan; Borthakur, Gautam; Konopleva, Marina; Pemmaraju, Naveen; Yang, Hui; Pierce, Sherry; Wierda, William; Bueso-Ramos, Carlos; Patel, Keyur P; Cortes, Jorge E; Ravandi, Farhad; Kantarjian, Hagop M; Garcia-Manero, Guillermo Journal: Lancet Issue: Volume 2:Issue 1(2015) Page Start: e12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
16. Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial. Issue 12 (December 2016) Authors: Cortes, Jorge E; De Souza, Carmino Antonio; Ayala, Manuel; Lopez, Jose Luis; Bullorsky, Eduardo; Shah, Sandip; Huang, Xiaojun; Babu, K Govind; Abdulkadyrov, Kudrat; de Oliveira, José Salvador Rodrigues; Shen, Zhi-Xiang; Sacha, Tomasz; Bendit, Israel; Liang, Zhizhou; Owugah, Tina; Szczudlo, Tomasz... Journal: Lancet Issue: Volume 3:Issue 12(2016) Page Start: e581 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
17. Targeted therapy in chronic myeloid leukemia. Issue 1 (January 2008) Authors: Jabbour, Elias; Cortes, Jorge E; Ghanem, Hady; O'Brien, Susan; Kantarjian, Hagop M Journal: Expert review of anticancer therapy Issue: Volume 8:Issue 1(2008) Page Start: 99 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
18. Tosedostat for the treatment of relapsed and refractory acute myeloid leukemia. (February 2014) Authors: DiNardo, Courtney D; Cortes, Jorge E Journal: Expert opinion on investigational drugs Issue: Volume 23:Number 2(2014:Feb.) Page Start: 265 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
19. Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study. Issue 8 (August 2019) Authors: Shih, Ya-Chen Tina; Cortes, Jorge E; Kantarjian, Hagop M Journal: Lancet Issue: Volume 6:Issue 8(2019) Page Start: e398 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
20. Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study. Issue 8 (August 2015) Authors: Martinelli, Giovanni; Oehler, Vivian G; Papayannidis, Cristina; Courtney, Rachel; Shaik, M Naveed; Zhang, Xiaoxi; O'Connell, Ashleigh; McLachlan, Karen R; Zheng, Xianxian; Radich, Jerald; Baccarani, Michele; Kantarjian, Hagop M; Levin, Wendy J; Cortes, Jorge E; Jamieson, Catriona Journal: Lancet Issue: Volume 2:Issue 8(2015) Page Start: e339 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗